Neuroleptic malignant syndrome

2,945views

Neuroleptic malignant syndrome

FOR MAY EXAM 4M 03/18

FOR MAY EXAM 4M 03/18

Disorders of fatty acid metabolism: Pathology review
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Eye conditions: Retinal disorders: Pathology review
Pyramidal and extrapyramidal tracts
Ascending and descending spinal tracts
Muscle spindles and golgi tendon organs
Somatosensory pathways
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Heparin-induced thrombocytopenia
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Migraine medications
General anesthetics
Local anesthetics
Neuromuscular blockers
Anti-parkinson medications
Medications for neurodegenerative diseases
Opioid antagonists
Antimetabolites for cancer treatment
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Platinum containing medications
Topoisomerase inhibitors
Ribonucleotide reductase inhibitors
Opioid agonists, mixed agonist-antagonists and partial agonists
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
Adrenergic antagonists: Beta blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Cardiac conduction system
Cardiac conduction velocity
ECG basics
ECG rate and rhythm
ECG intervals
ECG QRS transition
ECG axis
ECG normal sinus rhythm
Selective serotonin reuptake inhibitors
Serotonin and norepinephrine reuptake inhibitors
Tricyclic antidepressants
Monoamine oxidase inhibitors
Atypical antidepressants
Typical antipsychotics
Atypical antipsychotics
Lithium
Nonbenzodiazepine anticonvulsants
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Psychomotor stimulants
Extrinsic hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Thrombocytopenia: Clinical
Bleeding disorders: Clinical
Myeloproliferative neoplasms: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Premature ventricular contraction
Premature atrial contraction
Atrial fibrillation
Atrial flutter
Atrioventricular nodal reentrant tachycardia (AVNRT)
Wolff-Parkinson-White syndrome
Atrioventricular block
Bundle branch block
Long QT syndrome and Torsade de pointes
Ventricular tachycardia
Brugada syndrome
Ventricular fibrillation
Pulseless electrical activity
ECG cardiac hypertrophy and enlargement
ECG cardiac infarction and ischemia
Electrolyte disturbances: Pathology review
Postoperative evaluation: Clinical
Mesothelioma
Lung cancer and mesothelioma: Pathology review
Diffuse parenchymal lung disease: Clinical
Lung cancer: Clinical
Pleural effusion, pneumothorax, hemothorax and atelectasis: Pathology review
Restrictive lung diseases: Pathology review
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Sympathomimetics: Direct agonists
Muscarinic antagonists
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Arsenic poisoning
Cyanide poisoning
Lead poisoning
Methemoglobinemia
Ethylene glycol poisoning
Mercury poisoning
Paracetamol toxicity
Serotonin syndrome
Neuroleptic malignant syndrome
Medication overdoses and toxicities: Pathology review
Environmental and chemical toxicities: Pathology review
Pneumothorax
Pneumothorax: Clinical
Chest trauma: Clinical
Pleural effusion: Clinical
Ehlers-Danlos syndrome
Anatomy clinical correlates: Heart
Anatomy clinical correlates: Thoracic wall
Anatomy clinical correlates: Pleura and lungs
Anatomy clinical correlates: Mediastinum
Shock: Clinical

Flashcards

Neuroleptic malignant syndrome

0 of 11 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 1 complete

A 23-year-old man is brought to the emergency department after collapsing at a music festival on a hot summer day. The patient was with friends at an electronic dance show. According to his friends, the patient consumed a powdered drug at the concert. Afterwards, while dancing, he suddenly collapsed and started having tremors in the upper and lower extremities. He has a past medical history of depression, anxiety, and bipolar disorder, for which he takes fluoxetine, alprazolam as needed, and aripiprazole. Temperature is 39.0°C (102.2 °F), pulse is 132/min, respirations are 24/min, blood pressure is 172/85 mmHg, and O2 saturation is 97% on room air. On physical examination the patient is diaphoretic, mumbling incoherent sounds, and will not lie still in the gurney. The patient has increased muscle tone. Brief, sudden jerks are present throughout the upper and lower extremities. Which of the following clinical features is most specific to this patient's clinical presentation?

Key Takeaways

Neuroleptic malignant syndrome is a life-threatening neurological disorder most often caused by an adverse reaction to neuroleptic or antipsychotic drugs, which are used to treat mental health conditions, such as schizophrenia, bipolar disorder, and severe depression. Neuroleptic malignant syndrome typically presents with muscle rigidity, fever, autonomic instability, and cognitive changes such as delirium.